This review has demonstrated the prospects for discovery and validation of potential biomarkers in Africa. Currently available biomarkers and biomarkers sources were highlighted, as well as the application of high throughput methodologies for candidate biomarker discovery. Being a continent with a huge burden of cancer and mostly populated by low and middle income countries (LMIC), several challenges have been identified that militate against the routine application of proteomics to PCa research. The most promising urinary biomarkers which require further validation are the top 12 identified by targeted proteomics ; while the best serological biomarkers are the top 41 tumour associated antigens . All potential urinary and serological biomarkers that demonstrated ethnic trends are also worth investigating further for potential used for personalized management of PCa in Africa. There is a pressing need to develop cancer research initiatives and collaborations with partners within and outside of Africa. Potential PCa biomarkers discovered in African studies requires research and systematic validation as practiced in the developed world, with urine and blood based theranostic biomarkers offering a multi-pronged approach to diagnosis and treatment of PCa in Africa. Ethnic-tailored biomarkers for PCa management are required if personalized medicine is to become a reality among African populations. Collaborative research directed towards understanding the potential role of PCa immunotherapy in African patients should also be encouraged, both locally and internationally. Importantly, diagnostic focus should be redirected towards less invasive approaches to PCa management, to improve early screening and intervention in Africa. It is also suggest that a centralized specimen and proteome repository should be built for PCa in Africa, as this would provide a resource for better research into PCa burden among men of African descent.